Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE（PATH-STROKE）

Launched by SICHUAN PROVINCIAL PEOPLE'S HOSPITAL · Feb 20, 2024

Keywords

ClinConnect Summary

The PATH-STROKE clinical trial is investigating a tailored approach to antiplatelet therapy for patients who have experienced a non-cardiogenic ischemic stroke, which is a type of stroke caused by a blockage in blood flow to the brain. The main goal is to see if this personalized treatment can reduce the risk of heightened platelet activity—where platelets in the blood become overly active—within 30 days after the stroke. Researchers will also assess the safety and effectiveness of this guided therapy.

To be eligible for this trial, participants must be between 18 and 80 years old and have had their first stroke within the last one to three months, confirmed through brain imaging. They should also have been taking a daily dose of aspirin for at least eight days. It's important to note that individuals with a history of recurrent strokes, significant bleeding issues, or severe health problems may not qualify. Participants can expect to receive specialized care and monitoring during the study, helping to shape future treatments for stroke patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged from 18 to 80 years;
• • 2. Diagnosed with non-cardiogenic ischemic stroke according to WHO criteria, confirmed by cranial CT or MRI to exclude hemorrhagic stroke.;
• • 3. First stroke onset ≥ 1 month and ≤ 3 months;
• • 4. mRS Score \<=2 points;
• • 5. Undergoing antiplatelet therapy with 100mg aspirin daily for at least 8 days;
• • 6. Informed consent signed by the patient or their family member.
• Exclusion Criteria:
• • 1. History of recurrent stroke.
• • 2. History of gastrointestinal bleeding, intracranial hemorrhage, or other bleeding disorders.
• • 3. Contraindications or intolerance to antiplatelet therapy medications.
• • 4. Severe cardiac, pulmonary, hepatic, or renal insufficiency, or presence of severe comorbid conditions (e.g., end-stage malignant tumors, severe single/multiple organ failure).
• • 5. Poor compliance, inability to cooperate with study requirements.